This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

reputable news agency

proofread

Nonsignificant survival benefit seen for dabrafenib, trametinib in melanoma

Nonsignificant survival benefit seen for dabrafenib, trametinib in melanoma

For patients with resected stage III melanoma, adjuvant therapy with dabrafenib plus trametinib is associated with a nonsignificant benefit in terms of overall survival, according to a study published in the New England Journal of Medicine.

Georgina V. Long, M.D., Ph.D., from the University of Sydney, and colleagues randomly assigned 870 patients with resected stage III with BRAF V600 to receive 12 months of plus trametinib or two matched placebos. The median duration of follow-up was 8.33 and 6.87 years for dabrafenib plus trametinib and placebo, respectively.

The researchers found that for overall survival, the Kaplan-Meier estimates favored dabrafenib plus trametinib over placebo, but the benefit was not significant (hazard ratio, 0.80; 95% confidence interval, 0.62 to 1.01; P = 0.06). Across several prespecified subgroups, a consistent survival benefit was seen, including among 792 patients with melanoma with a BRAF V600E mutation (hazard ratio for death, 0.75; 95% confidence interval, 0.58 to 0.96). Significant benefits were also seen for dabrafenib plus trametinib versus placebo for relapse-free survival (hazard ratio for relapse or death, 0.52; 95% confidence interval, 0.43 to 0.63) and for distant metastasis-free survival (hazard ratio for distant metastasis or death, 0.56; 95% confidence interval, 0.44 to 0.71). There were no new reports of safety signals.

"Whether or how therapies administered after relapse may have reduced the effect of on overall survival is unclear," the authors write.

More information: Georgina V. Long et al, Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma, New England Journal of Medicine (2024). DOI: 10.1056/NEJMoa2404139

Journal information: New England Journal of Medicine

Copyright © 2024 HealthDay. All rights reserved.

Citation: Nonsignificant survival benefit seen for dabrafenib, trametinib in melanoma (2024, June 24) retrieved 28 June 2024 from https://medicalxpress.com/news/2024-06-nonsignificant-survival-benefit-dabrafenib-trametinib.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Benefit of adjuvant dabrafenib, trametinib persists in melanoma

 shares

Feedback to editors